Profile
Jennifer Lopansri has been Director of Clinical Operations for Prolexys Pharmaceuticals, Inc. since November, 2006.
Prior to joining Prolexys, she was an Associate Director of Clinical Operations for NPS Pharmaceuticals.
She held various positions at Searle Pharmaceuticals, the Pediatric Oncology Group and Abbott Laboratories.
Ms. Lopansri received a Bachelor's degree in Chemistry from Augustana College in 1993 and a Master's degree in Liberal Studies from Northwestern University in 2000.
Former positions of Jennifer Lopansri
| Companies | Position | End |
|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
| NPS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| Pediatric Oncology Group of Ontario | Corporate Officer/Principal | - |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Chief Tech/Sci/R&D Officer | - |
Training of Jennifer Lopansri
| Augustana College (Illinois) | Undergraduate Degree |
| Northwestern University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| Private companies | 3 |
|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
| Pediatric Oncology Group of Ontario |
- Stock Market
- Insiders
- Jennifer Lopansri
